Huang, Yan

Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2

Dai, C.-L., Tiwari, A. K., Wu, C.-P., Su, X.-D., Wang, S.-R., Liu, D.-G., Ashby, C. R., Huang, Y., Robey, R. W., Liang, Y.-J., et al. (2008) · Cancer Research

Drug Transport and Resistance MechanismsAntibiotic Resistance in Bacteria

Cited by 386

Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition

Zhang, X., Zhou, Y., Chen, C., Fang, W., Cai, X., Zhang, X., Zhao, M., Zhang, B., Jiang, W., Lin, Z., et al. (2019) · Journal for ImmunoTherapy of Cancer

Hepatitis B Virus StudiesCancer Immunotherapy and Biomarkers

Cited by 185

HIF-1α inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer

Luo, F., Lu, F.-T., Cao, J.-X., Ma, W.-J., Xia, Z.-F., Zhan, J.-H., Zeng, K.-M., Huang, Y., Zhao, H.-Y., & Zhang, L. (2022) · Cancer Letters

Cancer Immunotherapy and BiomarkersCancer, Hypoxia, and Metabolism

Cited by 95

Reporting of Immune Checkpoint Inhibitor Therapy–Associated Diabetes, 2015–2019

Liu, J., Zhou, H., Zhang, Y., Fang, W., Yang, Y., Huang, Y., & Zhang, L. (2020) · Diabetes Care

Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions

Cited by 55

The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer

Zheng, J., Zhao, S., Zhan, J., Zhuang, W., Chen, M., Jiang, W., Huang, Y., He, J., Hu, L., Pang, L., et al. (2026) · Cancer Discovery

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 2